Feb 24 (Reuters) - Bristol-Myers Squibb Co BMY.N:
U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL MYERS SQUIBB’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR OPDIVO® PLUS YERVOY® FOR PATIENTS WITH UNRESECTABLE OR METASTATIC MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT...
BRISTOL-MYERS SQUIBB CO - FDA ASSIGNS TARGET ACTION DATE OF JUNE 23, 2025
Source text: ID:nBw2tnHFDa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.